
    
      This is a randomized phase II clinical trial. The objective of the study is to assess
      efficacy and safety of brain radiotherapy combined with targeted therapy and simple targeted
      therapy in patients with asymptomatic NSCLC brain metastasis with gene sensitive mutation.
      Patients were randomized with equal allocation to Molecular targeted therapy alone or with
      brain radiotherapy. Study therapy continued until disease progression, unacceptable adverse
      event, or withdrawal of consent
    
  